Unnamed: 0,title,date,stock,sentiment
1307182.0,Recap: Vericel Q1 Earnings,2020-05-05 09:34:00-04:00,VCEL,neutral
1307183.0,"Vericel Q1 EPS $(0.100) Misses $(0.080) Estimate, Adj. EBTIDA Loss $700K, Sales $26.700M Beat $26.280M Estimate",2020-05-05 08:06:00-04:00,VCEL,negative
1307184.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,VCEL,positive
1307185.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,VCEL,neutral
1307186.0,"BTIG Maintains Buy on Vericel, Lowers Price Target to $21",2020-04-03 08:20:00-04:00,VCEL,negative
1307187.0,"Vericel Says Prelim. Q1 Unaudited Product Revenues Increased 21% YoY, Withdraws FY20 Guidance",2020-04-02 09:09:00-04:00,VCEL,positive
1307188.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,VCEL,negative
1307189.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,VCEL,negative
1307190.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,VCEL,neutral
1307191.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-18 11:37:00-04:00,VCEL,negative
1307192.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,VCEL,positive
1307193.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,VCEL,negative
1307194.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,VCEL,negative
1307195.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,VCEL,negative
1307196.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,VCEL,positive
1307197.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,VCEL,negative
1307198.0,40 Stocks Moving in Thursday's Pre-Market Session,2020-02-27 07:13:00-05:00,VCEL,neutral
1307199.0,80 Biggest Movers From Yesterday,2020-02-26 05:32:00-05:00,VCEL,neutral
1307200.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-02-25 12:24:00-05:00,VCEL,neutral
1307201.0,Vericel shares are trading lower after the company issued FY20 sales guidance below analyst estimates.,2020-02-25 09:16:00-05:00,VCEL,neutral
1307202.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,VCEL,negative
1307203.0,Vericel Sees FY20 Sales $141M-$146M vs $147.05M Est.,2020-02-25 08:05:00-05:00,VCEL,neutral
1307204.0,"Vericel Q4 EPS $0.2, Inline, Sales $39.4M Beat $38.99M Estimate",2020-02-25 08:04:00-05:00,VCEL,neutral
1307205.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,VCEL,neutral
1307206.0,"H.C. Wainwright Reiterates Buy on Vericel, Raises Price Target to $22",2020-02-03 07:12:00-05:00,VCEL,neutral
1307207.0,MediWound and Vericel's NexoBrid Receives $16.5M of Orders from the US Biomedical Advanced Research and Development Authority for Emergency Stockpiling,2020-01-06 06:36:00-05:00,VCEL,negative
1307208.0,Vericel shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY19 sales guidance above analyst estimates.,2019-11-05 08:45:00-05:00,VCEL,positive
1307209.0,Vericel Corporation  Sees FY19 Sales $116M-$118M vs $115.3M Est.,2019-11-05 08:03:00-05:00,VCEL,neutral
1307210.0,"Vericel Q3 EPS $0.07 Beats $(0.02) Estimate, Sales $30.5M Beat $26.84M Estimate",2019-11-05 08:03:00-05:00,VCEL,neutral
1307211.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,VCEL,negative
1307212.0,Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025,2019-10-09 15:09:00-04:00,VCEL,positive
1307213.0,"Benzinga's Top Upgrades, Downgrades For October 9, 2019",2019-10-09 09:37:00-04:00,VCEL,positive
1307214.0,"H.C. Wainwright Initiates Coverage On Vericel with Buy Rating, Announces $19 Price Target",2019-10-09 08:41:00-04:00,VCEL,neutral
1307215.0,Vericel And MediWound Announce Initiation Of US NexoBrid Expanded Access Treatment Protocol,2019-10-02 07:30:00-04:00,VCEL,neutral
1307216.0,Vericel Raises MACI And Epical Sales Guidance From $110M-$114M To $112M-$116M,2019-08-06 07:40:00-04:00,VCEL,neutral
1307217.0,"Vericel Q2 Adj. EPS $(0.05) Beats $(0.06) Estimate, Sales $26.2M Beat $24.12M Estimate",2019-08-06 07:39:00-04:00,VCEL,neutral
1307218.0,72 Biggest Movers From Yesterday,2019-05-08 06:17:00-04:00,VCEL,neutral
1307219.0,64 Stocks Moving In Tuesday's Mid-Day Session,2019-05-07 12:17:00-04:00,VCEL,neutral
1307220.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,VCEL,neutral
1307221.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-05-07 08:05:00-04:00,VCEL,neutral
1307222.0,"Vericel Q1 EPS $(0.07) Misses $(0.06) Estimate, Sales $21.81M Miss $22.88M Estimate",2019-05-07 07:27:00-04:00,VCEL,negative
1307223.0,"MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid in N. America; MediWound to Receive Upfront Payment of $17.5M, $7.5M on U.S. BLA Approval, Up to $125M in Sales Milestones",2019-05-07 04:26:00-04:00,VCEL,positive
1307224.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,VCEL,positive
1307225.0,64 Biggest Movers From Yesterday,2019-04-18 05:17:00-04:00,VCEL,neutral
1307226.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,VCEL,negative
1307227.0,"Benzinga's Top Upgrades, Downgrades For February 28, 2019",2019-02-28 09:14:00-05:00,VCEL,positive
1307228.0,Needham Downgrades Vericel to Hold,2019-02-28 07:33:00-05:00,VCEL,neutral
1307229.0,72 Biggest Movers From Yesterday,2019-02-27 04:55:00-05:00,VCEL,neutral
1307230.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-26 12:18:00-05:00,VCEL,neutral
1307231.0,25 Stocks Moving In Tuesday's Pre-Market Session,2019-02-26 08:30:00-05:00,VCEL,neutral
1307232.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,VCEL,positive
1307233.0,Vericel Sees FY19 Net Product Sales $108M-$112M,2019-02-26 07:48:00-05:00,VCEL,neutral
1307234.0,"Vericel Q4 EPS $0.11 Beats $0.04 Estimate, Sales $31.335M Beat $28.68M Estimate",2019-02-26 07:47:00-05:00,VCEL,neutral
1307235.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,VCEL,neutral
1307236.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,VCEL,positive
1307237.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,VCEL,neutral
1307238.0,"Benzinga's Top Upgrades, Downgrades For January 29, 2019",2019-01-29 09:15:00-05:00,VCEL,positive
1307239.0,"Oppenheimer Initiates Coverage On Vericel with Outperform Rating, Announces $23 Price Target",2019-01-29 07:59:00-05:00,VCEL,neutral
1307240.0,Vericel Highlights Publication Of Outcomes Data For 954 Burn Patients With Epicel In 'Journal Of Burn Care And Research'; Says Data Showed 'increased survival rate for patients treated with Epicel...',2019-01-04 10:02:00-05:00,VCEL,positive
1307241.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,VCEL,neutral
1307242.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,VCEL,neutral
1307243.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:25:00-05:00,VCEL,neutral
1307244.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,VCEL,negative
1307245.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,VCEL,neutral
1307246.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,VCEL,negative
1307247.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,VCEL,neutral
1307248.0,Mid-Afternoon Market Update: On Deck Capital Jumps On Earnings Beat; Invacare Shares Plummet,2018-11-06 14:30:00-05:00,VCEL,positive
1307249.0,60 Stocks Moving In Tuesday's Mid-Day Session,2018-11-06 12:36:00-05:00,VCEL,neutral
1307250.0,Mid-Day Market Update: Crude Oil Down 2%; ConvergeOne Shares Spike Higher,2018-11-06 12:00:00-05:00,VCEL,negative
1307251.0,Shares of Vericel are trading up 38.2% after the company beat Q3 earnings estimates and raised guidance.,2018-11-06 11:28:00-05:00,VCEL,positive
1307252.0,Mid-Morning Market Update: Markets Open Higher; CVS Health Earnings Beat Estimates,2018-11-06 10:25:00-05:00,VCEL,neutral
1307253.0,Vericel Raises FY18 Total Net Product Sales Guidance From $80M-$83M To $87M-$90M,2018-11-06 07:37:00-05:00,VCEL,neutral
1307254.0,"Vericel Q3 EPS $(0.02) Beats $(0.11) Estimate, Sales $22.5M Beat $18.14M Estimate",2018-11-06 07:37:00-05:00,VCEL,neutral
1307255.0,Q3 Earnings Preview For Vericel,2018-11-05 13:58:00-05:00,VCEL,neutral
1307256.0,Deerfield Management Shows a 6.15% Stake in Vericel,2018-10-22 06:17:00-04:00,VCEL,neutral
1307257.0,"Stocks Which Set New 52-Week High Yesterday, October 4th",2018-10-05 09:20:00-04:00,VCEL,neutral
1307258.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,VCEL,neutral
1307259.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,VCEL,neutral
1307260.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,VCEL,neutral
1307261.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,VCEL,neutral
1307262.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-09-05 08:01:00-04:00,VCEL,neutral
1307263.0,41 Stocks Moving In Friday's Mid-Day Session,2018-08-17 12:22:00-04:00,VCEL,neutral
1307264.0,Vericel Files For $200M Mixed Shelf Offering,2018-08-16 16:58:00-04:00,VCEL,neutral
1307265.0,77 Biggest Movers From Yesterday,2018-08-08 06:04:00-04:00,VCEL,neutral
1307266.0,64 Stocks Moving In Tuesday's Mid-Day Session,2018-08-07 13:01:00-04:00,VCEL,neutral
1307267.0,Mid-Morning Market Update: Markets Open Higher; Emerson Electric Earnings Beat Estimates,2018-08-07 10:24:00-04:00,VCEL,neutral
1307268.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,VCEL,negative
1307269.0,36 Stocks Moving In Tuesday's Pre-Market Session,2018-08-07 08:04:00-04:00,VCEL,neutral
1307270.0,Vericel shares up 16.7% after the company beat Q2 sales estimates and raised 2018 sales guidance,2018-08-06 17:31:00-04:00,VCEL,positive
1307271.0,Vericel Raises FY18 Sales Guidance From $73M-$78M To $80M-$83M vs $78.12M Est.,2018-08-06 17:03:00-04:00,VCEL,neutral
1307272.0,"Vericel Q2 Adj. EPS $(0.12), Inline, Sales $19.011M Beat $18.62M Estimate",2018-08-06 17:02:00-04:00,VCEL,neutral
1307273.0,Vericel's Earnings Preview,2018-08-06 08:47:00-04:00,VCEL,neutral
1307274.0,38 Biggest Movers From Yesterday,2018-07-18 05:47:00-04:00,VCEL,neutral
1307275.0,"Benzinga's Top Upgrades, Downgrades For July 16, 2018",2018-07-16 09:03:00-04:00,VCEL,positive
1307276.0,Ladenburg Thalmann Upgrades Vericel to Buy,2018-07-16 07:51:00-04:00,VCEL,neutral
1307277.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,VCEL,neutral
1307278.0,Verical Added To Russell 3000,2018-06-25 08:30:00-04:00,VCEL,neutral
1307279.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,VCEL,neutral
1307280.0,Vericel Prices 5M Share Offering @$13/Share,2018-05-31 20:16:00-04:00,VCEL,positive
1307281.0,44 Stocks Moving In Thursday's Mid-Day Session,2018-05-31 12:42:00-04:00,VCEL,neutral
1307282.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,VCEL,positive
1307283.0,28 Stocks Moving In Thursday's Pre-Market Session,2018-05-31 08:22:00-04:00,VCEL,neutral
1307284.0,Vericel Shares Down 6.1% After Hours Following Announcement Of 3.75M Share Common Stock Offering,2018-05-30 17:20:00-04:00,VCEL,positive
1307285.0,7 Stocks Moving In Wednesday's After-Hours Session,2018-05-30 17:08:00-04:00,VCEL,neutral
1307286.0,Vericel Reports Offering Of 3.75M Shares Of Common Stock,2018-05-30 16:01:00-04:00,VCEL,positive
1307287.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,VCEL,positive
1307288.0,"Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings",2018-05-16 08:10:00-04:00,VCEL,neutral
1307289.0,"Vericel Q1 EPS $(0.21) Misses $(0.13) Estimate, Sales $18.027M Beat $16.82M Estimate",2018-05-08 07:17:00-04:00,VCEL,negative
1307290.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,VCEL,neutral
1307291.0,Companies Holding Analyst/Investor Days Today Include Vericel and Mylan; Carnival Corp Holding Annual Shareholder Meeting Today,2018-04-11 06:54:00-04:00,VCEL,neutral
1307292.0,"The Week Ahead: Zuckerberg Goes To Washington, Big Banks Get Earnings Season Underway",2018-04-09 12:38:00-04:00,VCEL,neutral
1307293.0,36 Biggest Movers From Yesterday,2018-04-05 04:40:00-04:00,VCEL,neutral
1307294.0,Vericel Shares Up 17.1%; Earlier Leerink Partners Initiated Coverage At Outperform With a $15 Price Target,2018-04-04 14:31:00-04:00,VCEL,positive
1307295.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-04-04 12:50:00-04:00,VCEL,neutral
1307296.0,Vericel Publishes Results From Phase 3 SUMMIT Extension Study Showing Sustained Clinical Benefit Of MACI Out To 5 Years,2018-03-23 08:31:00-04:00,VCEL,positive
1307297.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-03-06 12:27:00-05:00,VCEL,neutral
1307298.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-03-06 08:09:00-05:00,VCEL,neutral
1307299.0,32 Biggest Movers From Yesterday,2018-03-06 05:08:00-05:00,VCEL,neutral
1307300.0,"Vericel Shares Now Up 43% Into Close; Co. Earlier Issued Strong Q4 Results, Said Expecting FY18 Sales $73M-$78M vs $70.2M Est.",2018-03-05 15:57:00-05:00,VCEL,positive
1307301.0,Mid-Afternoon Market Update: U.S. Stocks Turn Higher; Dow Gains Over 200 Points,2018-03-05 14:30:00-05:00,VCEL,positive
1307302.0,28 Stocks Moving In Monday's Mid-Day Session,2018-03-05 12:32:00-05:00,VCEL,neutral
1307303.0,Mid-Day Market Update: Vericel Surges After Strong Q4 Results; Smith Micro Software Shares Fall,2018-03-05 12:01:00-05:00,VCEL,positive
1307304.0,Vericel Shares Up 9.0% Following Q4 Earnings Beat,2018-03-05 08:54:00-05:00,VCEL,positive
1307305.0,"Vericel Reports Q4 EPS $0.01 vs $(0.07) Est., Sales $23.4M vs $18.8M Est.",2018-03-05 07:33:00-05:00,VCEL,neutral
1307306.0,"6 Stocks To Watch For March 5, 2018",2018-03-05 05:02:00-05:00,VCEL,neutral
1307307.0,"Earnings Scheduled For March 5, 2018",2018-03-05 04:24:00-05:00,VCEL,neutral
1307308.0,"UPDATE: Piper Jaffray On Vericel Highlights Co. Partnered Its RegenMed Products With ICT In China, Received $5.1M In Cash, Warrants, Is Eligible For Up To $8M In Milestone Payments",2018-01-02 11:42:00-05:00,VCEL,neutral
1307309.0,Vericel Shares Spike ~$0.20 Over Last Few Mins As Traders Circulate Note From Piper Jaffray Showing Increased Price Target To New Street High Of $9,2018-01-02 11:40:00-05:00,VCEL,positive
1307310.0,Vericel to Receive $5.1M Due to a Licensing Agreement with Innovative Cellular Therapeutics,2018-01-02 08:18:00-05:00,VCEL,positive
1307311.0,"Vericel Enters into Expanded $25M Debt Facilities with Silicon Valley Bank and MidCap Financial, Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit",2017-12-07 08:05:00-05:00,VCEL,neutral
1307312.0,"Vericel Shares Spike To Session High, Now Paring Gains As Traders Circulating Chatter On Social Media The Co.'s MACI Implant Is Now Being Considered Medically Necessary By CareFirst Blue Cross/Blue Shield",2017-11-21 14:25:00-05:00,VCEL,positive
1307313.0,45 Stocks Moving In Tuesday's Mid-Day Session,2017-11-07 12:41:00-05:00,VCEL,neutral
1307314.0,"Vericel Reports Q3 EPS $(0.16) vs $(0.16) Est., Sales $14.26M vs $13.88M Est.",2017-11-07 07:19:00-05:00,VCEL,neutral
1307315.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,VCEL,neutral
1307316.0,20 Biggest Mid-Day Losers For Thursday,2017-10-05 12:52:00-04:00,VCEL,negative
1307317.0,Mid-Day Market Update: Onvia Climbs On Acquisition News; Intellicheck Shares Plummet,2017-10-05 12:14:00-04:00,VCEL,positive
1307318.0,Vericel Surrenders 6 Days Of Gains,2017-10-05 11:15:00-04:00,VCEL,positive
1307319.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Beat Views,2017-10-05 10:13:00-04:00,VCEL,neutral
1307320.0,Vericel Reports Plans For Further Expansion Of MACI Sales Force In 2018,2017-10-05 07:08:00-04:00,VCEL,neutral
1307321.0,Vericel Corp Higher For Fourth Day In A Row,2017-09-29 13:44:00-04:00,VCEL,neutral
1307322.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-12 08:04:00-04:00,VCEL,neutral
1307323.0,15 Biggest Mid-Day Gainers For Wednesday,2017-08-30 12:34:00-04:00,VCEL,neutral
1307324.0,Archon Capital Management Reports 7.56% Stake In Vericel,2017-08-28 12:40:00-04:00,VCEL,neutral
1307325.0,20 Biggest Mid-Day Gainers For Wednesday,2017-08-09 12:36:00-04:00,VCEL,neutral
1307326.0,"Vericel Q2 EPS $(0.07) vs $(0.20) Est., Sales $16.95M vs $12.85M Est.",2017-08-09 07:43:00-04:00,VCEL,neutral
1307327.0,"BTIG Research Initiates Coverage On Vericel with Buy Rating, Announces $6.00 Price Target",2017-06-21 06:29:00-04:00,VCEL,neutral
1307328.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-06-07 08:05:00-04:00,VCEL,neutral
1307329.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-05-10 08:24:00-04:00,VCEL,neutral
1307330.0,"Vericel Reports Q1 EPS $(0.31) vs $(0.14) Est., Sales $9.4M vs $14.4M Est.",2017-05-10 07:18:00-04:00,VCEL,neutral
1307331.0,Vericel Reports Received FDA RMAT Designation for Ixmyelocel-T for Treatment of Advanced Heart Faliure Due to Ischmeic Dilated Cardiomyopahy,2017-05-10 07:17:00-04:00,VCEL,positive
1307332.0,"Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for China, South Korea, other Countries in SE Asia; Upfront Payment of $6M, Up to $8M in Milestones",2017-05-10 07:08:00-04:00,VCEL,positive
1307333.0,Vericel Shares Small Pop Higher Related To PR Highlighting Outcomes Data From Over 950 Severe Burn Patients Treated With Epicel,2017-03-23 10:18:00-04:00,VCEL,negative
1307334.0,20 Stocks Moving In Monday's Pre-Market Session,2017-03-13 08:24:00-04:00,VCEL,neutral
1307335.0,"Earnings Scheduled For March 10, 2017",2017-03-10 04:28:00-05:00,VCEL,neutral
1307336.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-02-21 08:58:00-05:00,VCEL,neutral
1307337.0,Vericel Receives FDA Fast Track Designation for Ixmyelocel-T,2017-02-21 07:41:00-05:00,VCEL,neutral
1307338.0,15 Biggest Mid-Day Gainers For Wednesday,2017-02-01 13:04:00-05:00,VCEL,neutral
1307339.0,Vericel Up 17% Premarket On PR Earlier This Morning Highlighting The First MACI Implant In The U.S.,2017-02-01 09:08:00-05:00,VCEL,neutral
1307340.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-02-01 08:18:00-05:00,VCEL,neutral
1307341.0,Vericel +25% Premarket @ $3.25 After Co Announces First MACI Implant in US to Treat Symptomatic Cartilage Defects of the Knee,2017-02-01 07:26:00-05:00,VCEL,neutral
1307342.0,A Preview Of January PDUFA Dates,2016-12-28 11:10:00-05:00,VCEL,neutral
1307343.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-12-22 08:31:00-05:00,VCEL,neutral
1307344.0,Mid-Morning Market Update: Markets Open Higher; Adobe Beats Q4 Expectations,2016-12-16 09:40:00-05:00,VCEL,neutral
1307345.0,Vericel Corp. Prices 6.2M Share Offering At $2.75/Share,2016-12-16 09:14:00-05:00,VCEL,positive
1307346.0,15 Stocks Moving In Friday's Pre-Market Session,2016-12-16 08:42:00-05:00,VCEL,neutral
1307347.0,Mid-Afternoon Market Update: Fed Raises Benchmark Interest Rate; Crude Oil Down Over 2%,2016-12-14 14:16:00-05:00,VCEL,negative
1307348.0,15 Biggest Mid-Day Gainers For Wednesday,2016-12-14 12:29:00-05:00,VCEL,neutral
1307349.0,Mid-Day Market Update: Vericel Surges On Awaited FDA Approval; Proteon Therapeutics Shares Drop,2016-12-14 12:01:00-05:00,VCEL,positive
1307350.0,Mid-Morning Market Update: Markets Mostly Lower; Nordson Beats Q4 Views,2016-12-14 10:06:00-05:00,VCEL,negative
1307351.0,Vericel Soars 50% On Awaited FDA Approval,2016-12-14 09:25:00-05:00,VCEL,positive
1307352.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-14 08:36:00-05:00,VCEL,neutral
1307353.0,Vericel +55.7% Premarket @$4.05 Following Announcement Tuesday of FDA Approval of First Autologous Cellularized Scaffold For The Repair Of Cartilage Defects Of The Knee,2016-12-14 06:22:00-05:00,VCEL,positive
1307354.0,Vericel +34% After-Hours @$3.50 Following Announcement of FDA Approval of First Autologous Cellularized Scaffold For The Repair Of Cartilage Defects Of The Knee,2016-12-13 18:02:00-05:00,VCEL,positive
1307355.0,FDA Approves First Autologous Cellularized Scaffold for Repair of Cartilage Defects of the Knee,2016-12-13 17:55:00-05:00,VCEL,neutral
1307356.0,Vericel Enters Distribution Agreement with Sartin's Vital Care -8K,2016-11-25 06:07:00-05:00,VCEL,positive
1307357.0,"Vericel Reports Q3 Sales $10.9M vs $12.5M Est., Adj. EPS $(0.27) vs $(0.28) Est.",2016-11-07 16:51:00-05:00,VCEL,neutral
1307358.0,Vericel Spikes to High of $2.59 on Volume,2016-08-24 09:58:00-04:00,VCEL,neutral
1307359.0,"Vericel Reports Q2 Adj Loss ($0.21)/Share vs Est Loss/Share ($0.16), Rev $12.8M vs $15.05M Est",2016-08-08 16:11:00-04:00,VCEL,negative
1307360.0,"Vericel Reports Q1 Adj. EPS $(0.08) vs $(0.25) Est., Sales ~$14.1M vs $11.6M Est.",2016-05-10 07:32:00-04:00,VCEL,neutral
1307361.0,Vericel Entered into Services Agreement with Dohmen Life Science Services for Certain Administrative and Clinical Support Services for Carticel -8K,2016-04-11 17:15:00-04:00,VCEL,positive
1307362.0,Bank of America Downgrades Vericel to Neutral,2016-04-05 07:05:00-04:00,VCEL,neutral
1307363.0,"Vericel Shares Bouncing Off Lows, Trading At $4.40/Share",2016-04-04 12:28:00-04:00,VCEL,positive
1307364.0,Vericel Shares Halted on Circuit Breaker,2016-04-04 12:24:00-04:00,VCEL,positive
1307365.0,Shares of Vericel Resume Trade; Stock Now Down 22%,2016-04-04 12:22:00-04:00,VCEL,positive
1307366.0,"UPDATE: Vericel Shares Halted on Circuit Breaker, Now Down 12.1%",2016-04-04 12:16:00-04:00,VCEL,positive
1307367.0,"Shares of Vericel Open for Trade; Stock Plunges Into Negative Territory, Now Down ~5% for Session",2016-04-04 12:15:00-04:00,VCEL,negative
1307368.0,Vericel To Resume Trading At 12:15pm EST,2016-04-04 11:54:00-04:00,VCEL,neutral
1307369.0,"UPDATE: Vericel Says ixCELL-DCM Met Primary Endpoint, Incidence of Adverse Events Comparable to or Lower Than Patients in Placebo Group",2016-04-04 11:46:00-04:00,VCEL,negative
1307370.0,UPDATE: Vericel Announces Patients Treated with Ixmyelocel-T had 37% Reduction in Clinical Events Compared to Placebo,2016-04-04 11:46:00-04:00,VCEL,neutral
1307371.0,"Vericel Offers Phase 2 ixCELL-DCM Trial of Ixmyelocel-T Results at AAC, Published in The Lancet",2016-04-04 11:45:00-04:00,VCEL,neutral
1307372.0,Vericel Shares Halted News Pending,2016-04-04 11:40:00-04:00,VCEL,positive
1307373.0,"Vericel Reports Publication of Trial Rationale, Study Design for Phase 2b ixCELL-DCM Trial of Ixmyelocal-T for Heart Failure Due to Ischemic Dilated Cardiomyopathy",2016-03-28 08:33:00-04:00,VCEL,negative
1307374.0,"Ladenburg Thalmann Cuts Vericel 2016 Revs Est. From $57.4M To $56.8M & EPS Est. From $(0.66) To $(0.79), Maintains Buy & $8.45 PT",2016-03-14 13:15:00-04:00,VCEL,negative
1307375.0,"Vericel Reports Q4 EPS $(0.28) vs $(0.15) Est., Sales $15.4M vs $17.4M Est.",2016-03-14 07:47:00-04:00,VCEL,neutral
1307376.0,Benzinga's Top Upgrades,2016-03-11 08:35:00-05:00,VCEL,positive
1307377.0,Needham Upgrades Vericel to Buy,2016-03-11 07:41:00-05:00,VCEL,neutral
1307378.0,Vericel +14% Premarket @$4.50,2016-03-11 07:34:00-05:00,VCEL,neutral
1307379.0,Mid-Afternoon Market Update: Vericel Jumps On Positive Phase 2b ixCELL-DCM Data; Energy Focus Shares Slide,2016-03-10 14:59:00-05:00,VCEL,positive
1307380.0,Mid-Day Market Update: US Stocks Turn Lower; Omega Protein Shares Drop Following Q4 Results,2016-03-10 12:07:00-05:00,VCEL,negative
1307381.0,Mid-Morning Market Update: Markets Open Higher; Dollar General Profit Beats Expectations,2016-03-10 09:50:00-05:00,VCEL,positive
1307382.0,"Vericel Shares Up $1.33 Pre-Market On Positive Phase 2b ixCELL-DCM Data, Up 64% On The Morning At $3.41/Share",2016-03-10 08:28:00-05:00,VCEL,positive
1307383.0,Vericel Offers Top-Line Results from Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to IDC: Study Met Primary Endpoint,2016-03-10 08:10:00-05:00,VCEL,negative
1307384.0,"Vericel Corp Says FDA Provided Prescription Drug User Fee Act Goal Update Of Jan 3, 2017, Accepts Filing Of BLA For MACI",2016-03-07 09:24:00-05:00,VCEL,positive
1307385.0,"Vericel Announces FDA Approval of Epicel HDE Supplement, Revised Label Includes Indiation For Use In Pediatric Patients",2016-02-22 08:31:00-05:00,VCEL,positive
1307386.0,Vericel Moving Up Following Submission Of Biologics Licence Application To The FDA,2016-01-05 10:02:00-05:00,VCEL,neutral
1307387.0,Vericel Submits Biologics License Application To FDA For MACI Treatment For Cartilage Defects In Knees,2016-01-04 16:08:00-05:00,VCEL,negative
1307388.0,Vericel Submits HDE Supplement to the FDA to Change the Labeled Indications for Use and Add Pediatric Labeling for Epicel,2015-12-08 08:03:00-05:00,VCEL,neutral
1307389.0,"Vericel Reports Q3 EPS ($0.26) vs. Est. ($0.25), Rev. $11.3M vs. Est. $10.5M",2015-11-13 07:30:00-05:00,VCEL,neutral
1307390.0,"Vericel Corp Reports Q2 Loss $0.16 Vs Est Loss $0.21, Sales $13.590M vs Est $11.31M",2015-08-12 07:31:00-04:00,VCEL,negative
1307391.0,Vericel Reports Plan to Submit HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel,2015-07-14 08:00:00-04:00,VCEL,neutral
1307392.0,Vericel Files Mixed-Securities Shelf For Up to $100M,2015-06-29 16:46:00-04:00,VCEL,neutral
1307393.0,US Stock Futures Signal Higher Start On Wall Street,2015-06-10 07:30:00-04:00,VCEL,neutral
1307394.0,Vericel Announces Plan to Submit Biologics License Application to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee,2015-06-10 07:01:00-04:00,VCEL,negative
1307395.0,"Vericel Reports Q1 Loss $0.27 Vs Est Loss $0.21, Sales $10.8M Vs Est $11.13M",2015-05-14 16:07:00-04:00,VCEL,negative
1307396.0,Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study of MACI Implant,2015-03-25 07:31:00-04:00,VCEL,neutral
1307397.0,Morning Market Gainers,2015-03-24 09:40:00-04:00,VCEL,neutral
1307398.0,"Vericel Reports Q4 EPS -$0.17 Vs Est -$0.47, Sales $14.7M Vs Est $10.70M",2015-03-23 16:02:00-04:00,VCEL,neutral
